Patent ID: 11887701
Assignee: ELUCID BIOIMAGING INC.
Field: Medical technology (Instruments)
Classification: CPC G | IPC G

Claim 22:
23. A method of screening a candidate anti-inflammatory agent for atherosclerotic cardiovascular disease, the method comprising:
receiving a first input of non-invasively obtained imaging data related to a plaque from a first set of test subjects;
receiving a second input of molecular expression data from the first set of test subjects;
creating a training set comprising the first input and the second input;
training a neural network using the training set, the neural network configured to predict molecule levels based on the non-invasively obtained imaging data from the first set of test subjects;
receiving non-invasively obtained imaging data related to a plaque from each of a second set of test subjects who have been diagnosed with atherosclerotic cardiovascular disease;
for each test subject of the second set of test subjects:
generating virtual comics data that include predicted molecule levels of a respective test subject, by applying the neural network to the non-invasively obtained imaging data from the respective test subject;
providing the virtual comics data to a systems biology model of atherosclerotic cardiovascular disease to generate a test subject-specific systems biology model for the respective test subject, wherein
(i) the systems biology model represents a plurality of pathways associated with atherosclerotic cardiovascular disease,
(ii) the plurality of pathways include one or more pathways corresponding to potential targets of the candidate anti-inflammatory agent,
(iii) the systems biology model includes a disease-associated molecule level for each molecule in the systems biology model, and
(iv) the test subject-specific systems biology model includes predicted molecule levels that are updated from the disease-associated molecule level;

updating the test subject-specific systems biology model with information relating to an effect on inflammation by a candidate anti-inflammatory agent based on a known mechanism of action of the candidate anti-inflammatory agent; and
simulating a therapeutic response by the respective test subject to the candidate anti-inflammatory agent in the updated test subject-specific systems biology model to obtain a simulated therapeutic effect, wherein the simulated therapeutic effect is based on change in the predicted molecule levels in the updated test subject-specific systems biology model with and without the candidate anti-inflammatory agent.